Cipla Ltd.
BSE: 500087 | NSE: CIPLA
Large Cap | Pharmaceuticals & Drugs
1426.80
-11.95 (-0.83%) Cipla informs about press release
Date: 12-08-2021Cipla has informed that it enclosed press release dated 12th August 2021, titled ‘Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%’.
The above information is a part of company’s filings submitted to BSE.